Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Stock Has Consensus Price Target of $51.40

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) has been given a consensus recommendation of “Moderate Buy” by the seven research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $51.40.

A number of analysts recently commented on the stock. HC Wainwright upped their price objective on shares of Hemab Therapeutics from $52.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Weiss Ratings downgraded Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, September 25th. Wedbush boosted their price objective on Hemab Therapeutics from $55.00 to $64.00 and gave the company an “outperform” rating in a research report on Wednesday, August 12th. Finally, Jefferies Financial Group raised their price objective on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, July 13th.

Hemab Therapeutics Trading Up 1.2%

Shares of COAG stock opened at $28.70 on Thursday. The firm has a 50 day simple moving average of $43.34. Hemab Therapeutics has a 52-week low of $23.00 and a 52-week high of $55.42. The company has a market capitalization of $1.34 billion and a PE ratio of -1.16.

Hemab Therapeutics (NASDAQ:COAG) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.17). As a group, analysts forecast that Hemab Therapeutics will post -3.09 EPS for the current year.

Hedge Funds Weigh In On Hemab Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC acquired a new position in shares of Hemab Therapeutics during the 2nd quarter worth approximately $19,226,000. Braidwell LP bought a new stake in shares of Hemab Therapeutics during the 2nd quarter worth about $5,877,000. State Street Corp acquired a new position in Hemab Therapeutics in the 2nd quarter valued at about $2,825,000. Opaleye Management Inc. bought a new position in Hemab Therapeutics in the 2nd quarter valued at about $1,750,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Hemab Therapeutics during the second quarter worth approximately $688,000.

Hemab Therapeutics Company Profile

Hemab Therapeutics (NASDAQ: COAG) is a clinical-stage biopharmaceutical company developing treatments for serious and potentially life-threatening bleeding disorders. The company focuses on rare conditions for which existing therapies may be limited, inconvenient, or ineffective for some patients.

Hemab’s lead investigational program, HMB-001, is an engineered bispecific antibody designed to improve blood clotting by enhancing thrombin generation through inhibition of tissue factor pathway inhibitor.